Footshocks increases mean arterial pressure and heart rate. Systemic or intracerebroventricular (IVT) administration of losartan, a specific angiotensin AT 1 receptor antagonist, not only inhibited the pressor response to footshocks but resulted in vasodepression. Peripheral or IVT administration of PD 123319, a specific angiotensin AT 2 receptor antagonist, did not alter the haemodynamic response to footshocks. However, simultaneous blockade of angiotensin AT 1 and AT 2 receptors by combined systemic or central administration of losartan and PD 12319, eliminated the vasodepressor response to footshocks unmasked in losartan pretreated rats. Our data suggest that activation of peripheral or brain angiotensin AT 2 receptor mediated the vasodepressor response to footshocks in the presence
Introduction
Angiotensin II, the primary effector hormone of the renin-angiotensin system, has a wide range of physiological actions directed at target organs in the cardiovascular system. These include vasoconstriction of peripheral blood vessels through activation of smooth muscle cell angiotensin AT 1 receptors. In addition to the direct vasoconstrictor action on vascular smooth muscle, angiotensin II influences vascular tone due to its ability to enhance noradrenergic neuroeffector transmission. Findings from several studies indicate that angiotensin AT 1 receptors are involved in the enhancement of sympathetic transmission by angiotensin II. 1, 2 In effect, the angiotensin AT 1 receptor antagonist losartan, but not the angiotensin AT 2 receptor antagonist PD 123177, blocks the enhancement of vasoconstriction responses to renal sympathetic stimulation produced by angiotensin II in the dog 3 and in the pithed rat vasculature, 4 suggesting an action through stimulation of prejunctional angiotensin AT 1 receptors. The concept of a functional role of angiotensin AT 1 receptor in the regulation of sympathetic activity is supported by our previous findings showing that central or peripheral administration of losartan causes inhibition of the vasopressor response elicited by footshocks. antagonist may not be entirely due to blockade of the angiotensin AT 1 receptor. Angiotensin receptors comprise two major subtypes, AT 1 and AT 2 .
2 Since the angiotensin AT 2 receptor is not blocked by losartan, it should be expected that the functions mediated via this receptor might be enhanced during angiotensin AT 1 receptor blockade. When the angiotensin AT 1 receptor is blocked, plasma and tissue renin and angiotensins increase markedly; 6 angiotensin II may act on angiotensin AT 2 receptors which could have an opposite effect such as vasodilation. Thus, one could predict that during footshock-stress, increased levels of angiotensin II would bind to unblocked angiotensin AT 2 receptors leading to a vasodepressor response. In fact, several studies have demonstrated that angiotensin II can also induce endothelium-dependent relaxations in some types of blood vessels. It has been reported that angiotensin II can elicit a biphasic arterial pressure response in rabbits 7 and rats. 8 Furthermore, endothelium-dependent relaxations induced by angiotensin II have been reported in a variety of experimental preparations such as the fowl aorta 9 and canine renal and cerebral arteries. 10 The heterogeneity of the response to angiotensin II may be related to modulatory effects of the vascular endothelium or stimulation of different angiotensin II receptor subtypes. A few studies in rats suggest that the endothelium-dependent vasorelaxation by angiotensin II is mediated by angiotensin AT 2 receptors thereby counteracting the vasoconstrictor action of angiotensin II at the smooth muscle site. Indeed, in anaesthetized rats blockade of angiotensin AT 2 receptors enhances the angiotensin-induced pressor response. 8 In addition, it has been shown that angiotensin II degradation products evoked endothelium-dependent relaxations in rat and rabbit cerebral arterioles, presumably through the activation of angiotensin AT 2 receptor subtypes. 11, 12 Angiotensin II may act on angiotensin AT 2 receptor subtype, either directly or via the release of autacoids such as kinins and nitric oxide. 13, 14 In this respect, it has been shown that in cultured endothelial cells, angiotensin II increases nitric oxidedependent cyclic guanosine monophosphate (cGMP) production through the stimulation of the angiotensin AT 2 receptor, which in turn leads to an enhanced release of bradykinin. 15 Some of the actions of angiotensin II are centrally mediated. Indeed, in brain angiotensin II has a wide range of physiological actions which include increase in blood pressure, arginine-vasopressin release, promotion of drinking behaviour and natriuresis. 16 These actions have been attributed mainly to the activation of various signalling transduction pathways modulated by angiotensin type I receptor since they could be antagonized by AT 1 receptor blockers. 2, [17] [18] [19] Brain angiotensin also enhances adrenergic tone by central activation and facilitation of sympathetic transmission 20 and increasing catecholamine turnover in sympathetic brain nuclei. 21 Since central blockade of AT 1 receptor with losartan significantly attenuates the pressor response to sympathetic stimulation-induced haemorrhage, 22 immobilization stress 23 and footshocks, 5 a role for brain AT 1 receptors has been suggested in the facilitation of noradrenergic transmission and pressor response to stress. Indeed, in various brain nuclei relevant to cardiovascular control, AT 1 receptor activation regulates uptake, synthesis and release of noradrenaline and dopamine. 21, 24 The role of brain angiotensin AT 2 receptor is not as clear as the angiotensin AT 1 receptor, and no direct evidence for an involvement of central angiotensin AT 2 receptors in the sympathetic response to stress has been presented so far. AT 2 receptor is expressed at very high levels in the developing foetus and in the adult its expression is restricted in specialised nuclei in the brain involved in sensory and motor control such as the ventral thalamic nucleus and inferior olive; and in the locus coeruleus, an area rich in noradrenergic neurons, which are known to be activated by physiological challenges and stimuli that are considered stressors. 25 In addition, using a more sensitive method, small quantities were detected of AT 2 receptors in circumventricular organs, 26 areas anatomically related to structures such as the nucleus tractus solitarious (NTS), the dorsal motor nucleus of the vagus (DMV) and the rostral vetrolateral medulla (RVLM), all of which play an important role in the central mechanisms of sympathetic outflow control.
There is electrophysiological and biochemical evidence demonstrating an interaction between AT 1 and AT 2 receptor activation which have been shown to have antagonic effects. Since AT 1 and AT 2 receptors have been linked to modulation of mitogenJournal of Human Hypertension activated protein (MAP) kinases on catecholaminergic neurons, functional interactions between the two receptor subtypes was proposed as the key in angiotensin II-induced neuromodulatory actions. 27 When brain AT 1 receptors are blocked by losartan, it should be expected that the functions mediated via the AT 2 receptor might be enhanced.
Little is known about brain AT 2 receptor mediators mechanism underlying the actions of angiotensin II in vivo. It is known that AT 2 receptor mediate activation of the kinin and nitric oxide (NO) system. Evidence has accumulated for the existence of a brain kallikrein-kinin system 28 and bradykinin B 2 receptors have been characterised in brain structures in which the renin-angiotensin system is expressed and known to participate in the regulation of blood pressure. 29 In addition, NOS is also expressed in the same brain regions in which the renin-angiotensin system is localized, providing potential anatomical substrate for interactions between angiotensin II and NO. 30 Based on the anatomical and functional evidence, it appears that angiotensin II actions may be mediated by an interplay of central mechanisms involving kinins and nitric oxide.
In the present study, we tested the hypothesis that in losartan treated rats, footshocks would result in a vasodepressor response due not only to blockade of the angiotensin AT 1 receptor but also activation of the angiotensin AT 2 sites and the release of nitric oxide or kinins. Toward this end, we assessed the effect of systemic or intracerebroventricular administration of losartan and/or PD123319, on the cardiovascular response to footshocks. This experimental model is known to cause sympathoadrenal and neuroendocrine activation. 31 In addition, to ascertain the role of kinins or nitric oxide on the vasodepressor responses to footshocks, experiments were performed in the presence of losartan and/or icatibant (HOE 140), a kinin B 2 receptor antagonist or N G -nitro-L-arginine-methyl ester (L-NAME) a nitric oxide synthase inhibitor.
Materials and methods

Experimental protocol
Male Sprague-Dawley rats (160-190 g) were housed under controlled conditions of temperature and photoperiod (light on from 06.00 to 18.00) and were provided with free access to laboratory chow and water. In order to establish the effect of angiotensin receptor blockade on the stress-induced increases in blood pressure and heart rate, rats were subjected to mild inescapable footshocks. Animals were randomly distributed into the following groups: In a separate group of animals the same protocol was adopted as the first series except that rats were implanted with a cannula in the left lateral cerebroventricle, 32 1 mm caudal to the coronal suture and 1.5 mm lateral to the midsagittal suture, with the aid of a stereotaxic instrument and under pentobarbital anesthesia (40 mg/kg, i.p.). A minimum of 3 days was allowed for recovery. Single intracerebroventricular (IVT) injections were made with a Hamilton syringe fitted with a stop to prevent needle penetration past the cannula tip. Ventricular cannula placement was confirmed postmortem by examining the distribution of an IVT injection of 5 l of fast green dye, given before animal sacrifice. Data were used only if the dye was distributed in the four ventricles. Animals were randomly distributed into the following groups IVT-pretreated with: (1) Control: saline (5 l; n = 25); (2) losartan (100 g/5 l) (n = 27); (3) PD 123319 (100 g/5 l) (n = 8); (4) Pretreated with losartan + PD 123319 (n = 8); (5) Icatibant (HOE 140) (20 pmol/5 l) (n = 5); (6) losartan + icatibant (n = 9); (7) L-NAME (100 g/ 5 l) (n = 11); (8) losartan + L-NAME (n = 13).
Quantification of cardiovascular responses to footshocks
Blood pressure was measured by the tail-cuff method. Systolic and diastolic pressure and heart rate were recorded daily using a tail-cuff digital plethysmograph (LE 5000, LETICA Scientific Instruments, Barcelona, Spain). To minimise stress, rats were trained daily with the plethysmograph 1 week prior to the experiment. Moderate warming of the rats was standardised by placing the cage containing the rat into an oven (Memmert, 91126 Schwabach, Western Germany) (60 × 50 × 40 cm, internal dimensions) at 42°C, for 15 min immediately before cardiovascular parameters determination. Cardiovascular parameters were measured daily at the same time of the day during the training and experimental periods.
Thirty minutes (IVT) or 45 min (systemic) after drug treatment, the animals were transferred to a Plexiglas chamber with a copper rod floor where they received mild footshocks (2 Hz, 100 V, 5 ms, for 5 min) delivered by a Grass stimulator (Model S48). The rats were placed into the heating oven and after 10 min of heating, footshock-stimulation was performed inside the oven for a period of 5 min. Immediately after this procedure, measurements of the cardiovascular responses were taken. Basal mean arterial pressure and heart rate were determined before drug treatment and 5 min before the start of the experiment with footshocks. The mean arterial pressure and heart rate determined immediately before footshocks were considered as basal.
All data are expressed as mean arterial pressure calculated from the sum of diastolic blood pressure and one-third the pulse pressure, and are expressed as the means ± s.e.m. Statistical differences between groups were evaluated by one-way analysis of variance (ANOVA) and a value of P Ͻ 0.05 was considered significant.
Results
As shown in Figure 1 , footshocks caused a significant increase in mean arterial pressure and heart rate. Footshock stimulation in the presence of an angiotensin AT 1 receptor blocker, losartan given subcutaneously (10 mg/kg) or IVT (100 g/5 l) resulted in a consistent vasodepressor response, while heart rate response was not altered (heart rate response not shown). PD 123319 alone did not alter the haemodynamic response to footshocks. However, when losartan and PD 123319 were used in combination to block both angiotensin AT 1 and AT 2 receptor subtypes, the vasodepressor response was eliminated as compared with the response with losartan alone (Bonferroni P value, for losartan vs losartan + PD123319, P Ͻ 0.01). Therefore, peripheral or central blockade of the vasopressor response to electric stimulation by a selective angiotensin AT 1 receptor antagonist unmasked a vasodepressor response in these experiments, which was completely abolished by combined blockade of both receptor subtypes.
Systemic or central administration of icatibant (HOE 140) or L-NAME had no significant effect on the mean arterial pressure response to footshocks. However, icatibant or L-NAME blunted the vasodepressor response to footshocks unmasked in losartan-treated rats (Figure 2 ) (Bonferroni P value, for losartan vs losartan + L-NAME, P Ͻ 0.05; vs losartan + icatibant and losartan + indomethacin, P Ͻ 0.01). Therefore, vasopressor and vasodepressor response to footshocks was completely abolished by combined blockade of angiotensin AT 1 receptor and kinin B 2 receptor or nitric oxide synthase inhibition.
Heart rate response to footshocks was not altered by drug treatments, except that there was a significant reduction in heart rate response in IVTlosartan + icatibant group (changes in heart rate in bpm were: for the peripheral treated group: vehicle = 82.66 ± 5.1; losartan = 79.9 ± 6.3; PD123319 = 76.3 ± 3.7; losartan + PD123319 = 89.1 ± 3.8). For the IVT treated group: vehicle = 88.66 ± 7.1; losartan = 80.9 ± 4.3; L-NAME = 115 ± 4.2; L-NAME + losartan = 105 ± 3.6; icatibant = 74.16 ± 5.8; losartan + icatibant = 41.8 ± 5.88*; P Ͻ 0.01).
Discussion
Acute stress induced by footshocks causes sympathoadrenal activation with increases in arterial pressure and heart rate. 32 In our earlier study we have shown that central or peripheral blockade of angiotensin AT 1 receptors with losartan produces a dose-dependent inhibition of the vasopressor responses to sympathetic stimulation, probably due to a reduced rise of peripheral resistance because HOE-140) or L-NAME. Vehicle (n = 9-25); losartan (10 mg/kg, s.c., n = 8; 100 g/5 l, IVT, n = 27); icatibant (400 g/kg, i.p., n = 13; 20 pmol/5 l, IVT, n = 5); losartan + icatibant (n = 13 or 9); L-NAME (20 mg/kg, i.p., n = 14; 100 g/5 l, IVT, n = 14); losartan + L-NAME (n = 18 or 13). Values represent means ± s.e.m. *P Ͻ 0.05 and **P Ͻ 0.01 compared with vehicle (Bonfferoni P values, ANOVA).
heart rate response to footshocks was not affected by losartan. 5 In the present study we demonstrate that in addition to its inhibitory action on vasopressor response to footshocks, systemic or central angiotensin AT 1 receptors blockade with losartan, caused a vasodepressor response to footshocks. The vasodepressor response unmasked in the presence of losartan was blocked by peripheral or central injection of PD 123319, which is known to be a specific angiotensin AT 2 receptor antagonist, 33 thus supporting the hypothesis that the vasodepressor response is mediated, in part, by activation of the angiotensin Journal of Human Hypertension AT 2 receptor. The angiotensin AT 2 receptor antagonist by itself did not have any effect on the cardiovascular response to footshocks compared with the vehicle group, suggesting that the angiotensin AT 2 receptor may exert a vasodepressor response only when the angiotensin AT 1 receptor is blocked. Therefore, the combined blockade of angiotensin AT 1 and AT 2 receptors specifically and completely eliminates both the vasopressor and vasodepressor responses to endogenous angiotensin II, suggesting a role for angiotensin AT 2 receptor in the regulation of the sympathoadrenal response to footshocks.
It has been shown that selective stimulation of 34, 35 There is evidence that these actions are under inhibitory control by angiotensin AT 2 receptors. 36 Indeed, angiotensin AT 2 receptor antagonizes both pressor and growth effects of the angiotensin AT 1 receptor 37, 38 and the central mediated angiotensin-induced release of vasopressin and drinking. 39 In relation to the cardiovascular system it has been demonstrated that angiotensin II and angiotensin III can produce a biphasic arterial blood pressure response. The vasopressor response was mediated by angiotensin AT 1 while the vasodepressor response was related to angiotensin AT 2 receptors. 8 Furthermore, mice with targeted deletion of the AT 2 receptor is associated with vascular and renal hypersensitivity to angiotensin II, including sustained antidiuresis and hypertension. 39 Thus, the existence of an equilibrium between pressor AT 1 and depressor AT 2 receptor should be proposed. Consequently, when angiotensin II action is eliminated by AT 1 blockade, the actions of AT 2 receptor stimulation, ie, vasodepression, should be overexpressed.
The mechanism whereby brain AT 2 receptor mediates vasodepressor response to footshocks may be explained through the release of substances such as bradykinin or NO. 40 AT 2 receptor may exert its vasodepressor effect by stimulating local release of nitric oxide either directly or via kinins 13, 41 which together with blockade of the AT 1 receptor may have an vasodepressor effect.
The vasorelaxation in response to angiotensin II in the periphery may be due to the release of dilator substances from the endothelium induced by angiotensin AT 2 receptor stimulation. 40 Indeed, it has been shown that vasorelaxation in several experimental preparations is blocked by inhibitors of methylene blue, a soluble guanylyl cyclase inhibitor, suggesting a role for nitric oxide-guanylyl cyclase system. 11, 42 It could be that the angiotensin AT 2 receptor exerts its haemodynamics effects by stimulating local release of nitric oxide either directly or via kinins 13, 14, 41 which together with the blockade of the angiotensin AT 1 receptor may have an vasodilator effect. It has been reported that in cultured bovine aortic endothelial cells, angiotensin II induces a sixto seven-fold increase in the release of cGMP; this effect was abolished by a kinin antagonist and a nitric oxide synthesis inhibitor and markedly inhibited by an angiotensin AT 2 receptor antagonist, but only marginally inhibited by an angiotensin AT 1 receptor antagonist, 14 suggesting that angiotensinstimulated release of nitric oxide is predominantly due to stimulation of the angiotensin AT 2 receptor and may lead to an increase in the effect of kinins, stimulation of nitric oxide and increased cGMP formation. Also, in microvessels of the dog heart, it has been shown that angiotensins stimulate cGMP via either the angiotensin AT 2 receptor and/or a nonangiotensin AT 1 or AT 2 receptor (AT n ), kinins, and nitric oxide.
14 Our data of blockade of the vasodepressor response to footshocks with the kinin B 2 receptor antagonist or with nitric oxide synthase inhibition suggests that during blockade of the angiotensin AT 1 receptor, activation of angiotensin AT 2 or AT n receptors may lead to an increase in either tissue kinins concentration or the effect of kinins, and the subsequent release of nitric oxide. 43 In regard to the central nervous system, increasing evidence has suggested that there is a close interaction between NO and angiotensin II. 44 Although the present study does not provide direct evidence for the site of action of the NO-angiotensin II interaction, it could be proposed that it is mediated within brain structures known to alter sympathetic outflow such as the NTS, the DMV and the RVLM, all of which play important roles in the regulation of sympathetic activity. Moreover, NO synthase is widely distributed in the brain and is mainly located in the neurons and the vascular endothelium of several brain regions in which renin-angiotensin system is localised such as the NTS, the RVLM, and the DMV. 30 NO seems to act as a neurotransmitter or neuromodulator and it has been implanted in the inhibitory regulation of sympathoexcitatory neurons within the brain. 44 Further, it has been demonstrated that inhibition of NO formation in NTS increase sympathetic nerve activity in rabbits. 45 Angiotensin II increases NO release in many cell types, including cultured murine neuroblastoma cells, 46 vascular smooth muscle cells and cardiac cells, 14 and in the central nervous system where they exert opposite effects. 47 Kinin-generating systems are also present in brain areas related to cardiovascular control 28 and bradikynin B 2 receptors are expressed in brain areas related with blood pressure control. Indeed, microinjection of bradykinin into the NTS have been shown to produce a dose-dependent decrease in mean arterial pressure, a hypotension mainly determined by a decrease in the sympathetic system activity. 48 Our present results of a blockade of the vasodepressor response to footshocks with central administration of the kinin B 2 antagonist or inhibition of NO formation suggest that during blockade of the AT 1 receptor, activation of AT 2 receptors may lead to an increase in either brain kinins concentration or the effect of kinins, 43 which in turn may release NO. These substances, at different central sites, may shift toward a sympatho-inhibitory effect manifested as a hypotensor response to footshocks.
In conclusion, this study demonstrates that peripheral and brain AT 2 receptors plays a counterregulatory protective role mediated via kinins and nitric oxide against the pressor action of angiotensin II during stress. We speculate that footshocks and blockade of AT 1 receptors increases both circulating and brain renin and angiotensins, these angiotensins stimulate AT 2 receptors, which in turn may induce vasodepression via kinins and other autacoids.
